enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. FDA approves 1st new drug for schizophrenia in more ... - AOL

   www.aol.com/fda-approves-1st-drug-schizophrenia...

   The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb ...

3. Bristol Myers wins US FDA approval for new type of ...

   www.aol.com/news/us-fda-approves-bristol-myers...

   (Reuters) -The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the first new type of antipsychotic medicine in decades. The ...

4. Xanomeline/trospium chloride - Wikipedia

   en.wikipedia.org/wiki/Xanomeline/trospium_chloride

   The effectiveness of xanomeline/trospium chloride for the treatment of schizophrenia in adults was evaluated in two studies with identical designs. [2] Study 1 (NCT04659161) and study 2 (NCT04738123) were 5-week, randomized, double-blind, placebo-controlled, multi-center studies in adults with a diagnosis of schizophrenia according to DSM-5 ...

5. FDA approves new type of schizophrenia drug - AOL

   www.aol.com/news/fda-approves-type-schizophrenia...

   The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...

6. Lumateperone - Wikipedia

   en.wikipedia.org/wiki/Lumateperone

   Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the butyrophenone class. It is approved for the treatment of schizophrenia as well as bipolar depression, as either monotherapy or adjunctive therapy (with lithium or valproate). [2]

7. Roluperidone - Wikipedia

   en.wikipedia.org/wiki/Roluperidone

   Minerva believed that the findings of this second trial supported the claim that the drug was an effective agent for the treatment of negative symptoms in schizophrenia. However, in October 2022, FDA sent Minerva a refusal to file letter pertaining to the New Drug Application for roluperidone for treating negative symptoms in schizophrenia ...